Andere talen RAPT Therapeutics, Inc.

Aandelen

RAPT

US75382E1091

Geschatte realtime Cboe BZX Andere beurzen 19:20:38 30-04-2024			Variatie 5 dagen	Verschil t.o.v. 1 jan (%)
7,79 ^USD	-1,14%		-3,06%	-68,79%

09/04	RAPT Therapeutics kondigt veelbelovende resultaten aan van Fase 2-studie met tivumecirnon in combinatie met anti-PD-1 immunotherapie bij CPI-ervaren patiënten met hoofd-halskanker	CI
27/03	RAPT THERAPEUTICS, INC. : JPMorgan Chase is neutraal gestemd over het aandeel	ZM

Andere talen

Krijg toegang tot al het nieuws over alle bedrijven: mis nooit meer een winstgevende beleggingskans!

Gratis inschrijven

RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	09/04
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	09/04
RAPT Therapeutics Announces Promising Results from Phase 2 Trial of Tivumecirnon in Combination with Anti-PD-1 Immunotherapy in CPI-Experienced Head and Neck Cancer Patients	09/04
RAPT Therapeutics, Inc.(NasdaqGM:RAPT) dropped from S&P Biotechnology Select Industry Index	18/03
Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT	11/03
RAPT Therapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	07/03
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	07/03
RAPT Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results	07/03
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting	05/03
RAPT Therapeutics Announces Multiple Late-Breaking Presentations at the Upcoming American Association for Cancer Research (AACR) Annual Meeting	05/03
Pomerantz Law Firm Investigates Claims on Behalf of Investors of RAPT Therapeutics, Inc. - RAPT	03/03
RAPT Therapeutics, Inc. (RAPT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged Wrongdoings	26/02
North American Morning Briefing : S&P 500 Futures -2-	23/02
RAPT Therapeutics Shares Decline Following UBS Downgrade	22/02
North American Morning Briefing : Nvidia Ignites -2-	22/02
North American Morning Briefing : Stock Futures -2-	21/02
Sector Update: Health Care Stocks Lower Late Afternoon	20/02
Top Midday Decliners	20/02
RAPT Therapeutics Shares Plunge Premarket on FDA Study Hold	20/02
Two RAPT Therapeutics Studies Put on Hold by FDA After Adverse Event	20/02

Geen resultaten voor deze zoekopdracht

Al het nieuws Aanbevelingen van analisten Belangrijkste gebeurtenissen Insiders Transcripties Persberichten Officiële publicaties Andere talen Ideeën voor de handel MarketScreener-artikels MarketScreener-analyses

Andere talen RAPT Therapeutics, Inc.

Aandelen

RAPT

US75382E1091

Andere talen

Filters